Prf Technologies Ltd. · NASDAQ:PRFX
Prf Technologies — PainReform — Investor Presentation (July 2022)
19 slides from Prf Technologies's investor presentation, Jul 29, 2022
Slide 1: Investor Presentation July 2022
Investor Presentation July 2022
Slide 2: Forward-Looking Statements
2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, beliefs and intentions . Forward - looking statements can be identified by the use of forward - looking words such as “be
Slide 3: Executive Summary
3 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 Executive Summary ▪ Post - operative pain treatment is a growing market (~$12B) with a need for better therapeutics 1 o Local anesthetics provide pain relief for up to 6 hours and require augmentation with n on - steroid
Slide 4: Post-Operative Pain Management Market Overview
4 PainReform Ltd. | www.painreform.com Post Operative Pain Management Post - Operative Pain Management Market Overview ▪ The 2017 North America post - operative pain treatment market was estimated at ~$ 12 B and is expected to reach ~$ 16 B and $ 45 B world - wide by the end of 2026 1 ▪ Significant
Slide 5: Current Approaches in Post-Operative Analgesia Are Lacking
5 PainReform Ltd. | www.painreform.com Post Operative Pain Management Current Approaches in Post - Operative Analgesia Are Lacking ▪ Poor efficacy in acute pain control ▪ Not intended for the treatment of post - operative pain Short - Acting Opioids ▪ Repeated dosing required ▪ Inconsistent pain con
Slide 6: Prescription Opioids
6 PainReform Ltd. | www.painreform.com Post Operative Pain Management Prescription Opioids ▪ Prescription opioids can be used to treat moderate - to - severe pain and are often prescribed following surgery or injury ▪ In recent years, there has been a dramatic increase in the acceptance and use of p
Slide 7: Problem: State of Opioid Crisis in America
7 PainReform Ltd. | www.painreform.com Post Operative Pain Management Problem: State of Opioid Crisis in America ▪ 99 % of surgical patients receive opioids to manage post - surgical pain 1 and released with opiate prescription ▪ Approximately 11.4 million people misused opioids in 2016 and 2019 . 8
Slide 8: PainReform Solution: Post Operative Pain Management
8 PainReform Ltd. | www.painreform.com Post Operative Pain Management PainReform Solution: PRF - 110 Post Operative Pain Management ▪ PRF - 110 has the potential of reducing the consumption of opioids to manage post - surgical pain ▪ Studies have shown 48 hours of pain reduction in healthy volunteer
Slide 9: Manufacturing
9 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 Manufacturing ▪ Engaged Pharmaceutics International, Inc. (PII): ▪ US based contract manufacturing organization ( CMO ) ▪ Well experienced in sterile manufacturing ▪ PII is a premier, solutions - oriented, science driven
Slide 10: Timeline to NDA
10 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 : Timeline to NDA FDA agreed to PRF - 110 product designation of 505 (b)( 2 ) accelerated regulatory pathway for NDA approval FDA determined the CMC data adequate to proceed to Phase I study Phase I study demonstrated P
Slide 11: Additional competing products (approved and in development)
11 PainReform Ltd. | www.painreform.com Post Operative Pain Management Additional competing products (approved and in development): • Posimir by Durect ( “ DRRX ” ), held up at phase III due to safety profile of the matrix (synthetic polymer), FDA approval for only arthroscopic subacromial decompres
Slide 12: Safety
12 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 Safety ▪ PainReform carried out extensive FDA requested wound healing and related animal studies that showed: x PRF - 110 allows for normal wound healing of surgical incisions equal to both Naropin ® and saline without
Slide 13: Phase 2 Results in Hernia
13 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 Phase 2 Results in Hernia ▪ Efficacy » PRF - 110 provided post - operative pain control for up to 72 hours after a single application ▪ Safety » PRF - 110 was well tolerated ▪ Ease of use » Easy to use and compliant wit
Slide 14: Phase III Clinical Trial Protocol
14 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 : Phase III Clinical Trial Protocol ▪ Two, double blind, placebo control 72 - hour treatment period , studies planned (bunionectomy and hernia surgery). For each study: ▪ Three cohorts (n= ~ 400 ): PRF - 110 ; Naropin ®
Slide 15: PRF-110: Potential Best-In-Class
15 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110: Potential Best - In - Class Administration PRF - 110 viscosity and uniformity are highly suitable for standard surgical site administration. Efficacy Cross study comparison of Phase II data, 72 hours pain AUC Safety Me
Slide 16: Highly experienced management Team
16 PainReform Ltd. | www.painreform.com Post Operative Pain Management Highly experienced management Team Sigal Aviel, PhD, MBA, Chief Operating Officer ▪ Over 20 years of managerial experience in the Biotech industry. ▪ Former chief R&D officer at MediWound, a company specializing in deep burns and
Slide 17: Summary
17 PainReform Ltd. | www.painreform.com Post Operative Pain Management Summary Large Unmet Need in Non - Opioid Postoperative Pain Management 1 1 Market Watch Post - Operative Pain Management Market Size Analysis 2019 Report Innovative Formulation / Delivery System Opioid Epidemic Presents Significa
Slide 18: Key Statistics
18 PainReform Ltd. | www.painreform.com Post Operative Pain Management Key Statistics NASDAQ: PRFX Current Price (July 15, 22): $0.8 Shares Outstanding (4/11/22): 10.5 M Market Cap: $8.4 M Fiscal Year End: December 31 Inside Beneficial Ownership: 34.3%
Slide 19: Thank You
Thank You